Skip to main
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen is poised to make a major impact in the biotechnology industry with its innovative approach to targeting the Wnt pathway for tissue repair. With promising preclinical results for its lead drug candidate, SZN-8141, and a strong pipeline of other Wnt-based therapeutics, the company has the potential to become a leader in the treatment of retinal diseases. Additionally, the recent positive outcome from its partnership with Boehringer Ingelheim highlights the company's strong potential for growth and development. Investors can expect continued progress and potential market differentiation as Surrozen advances towards IND submission and initiation of clinical trials for its lead drug candidate.

Bears say

Surrozen is a clinical-stage biotechnology company currently facing risks to its investment thesis, including failure to secure adequate funding for operations and uncertain commercial success of its developmental candidates in the competitive biopharmaceutical market. The company's financials for 1Q26 showed negative earnings per share and a net loss, signaling potential financial instability. Its product candidate, SZN-8141, may offer a potential advantage due to its bifunctional Wnt/VEGF antibody design, but the company's overall outlook remains uncertain.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.